Trial Profile

A First-in-Human Study of PRD001 in Healthy Participants, Assessment of Safety, Tolerability and Pharmacokinetics of Single/Multiple Doses

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PRD 001 (Primary)
Indications Hyperlipoproteinaemia type II; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Focus Adverse reactions; First in man
Sponsors PRD Therapeutics

Most Recent Events

06 Jul 2025 New trial record
27 Jun 2025 According to a PRD Therapeutics media release, dosing in this trial has been initiated.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com